SUMMARY
The research interests of Anastasia Zekeridou, M.D., Ph.D., are on neurological autoimmunity and paraneoplastic neurological diseases. Her research is focused on elucidating the link between cancer and neurological autoimmunity and mechanisms of paraneoplastic neurological disease, as well as neurological complications of cancer immunotherapy. This includes the identification of novel neural autoantibody biomarkers of both cancer and neurological autoimmunity. Additionally, Dr. Zekeridou focuses on the clinical, serological and cancer associations of patients with neurological autoimmunity and neural autoantibodies.
Focus areas
- Neural autoantibody biomarkers. Dr. Zekeridou's research aims to discover neural autoantibodies in both the serum and spinal fluid of patients with neurological autoimmunity, paraneoplastic neurological syndromes or cancer.
- Paraneoplastic neurological syndromes. Dr. Zekeridou is interested in the pathophysiology of paraneoplastic neurological syndromes, as well as the clinical presentations, serological accompaniments, cancer associations, treatments and outcomes of patients with paraneoplastic neurological syndromes.
- Neurological complications of immune-checkpoint inhibitor cancer immunotherapy. Dr. Zekeridou studies pathophysiology, clinical presentation, treatment and outcomes of patients with cancer treated with immune-checkpoint inhibitor cancer immunotherapy who develop neurological complications.
Significance to patient care
Understanding the disease mechanisms, developing diagnostic biomarkers, identifying the clinical presentations and discovering optimal treatments to ensure better outcomes is crucial for patients with neurological autoimmunity, paraneoplastic neurological syndromes or complications of immune-checkpoint inhibitor cancer immunotherapy.